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SUMMARY AT A GLANCE
This review manuscript evaluated the magni-
tude of ESA dose reduction in relation to op-
timal or suboptimal iron treatment. Optimal
iron therapy should allow reduction of ESA
dosages, allowing a possible cost saving.
ABSTRACT:
Aim: Higher dosages of erythropoiesis-stimulating agents (ESAs) have been
associated with adverse effects. Intravenous iron is used to optimize ESA re-
sponse and reduces ESA doses in haemodialysis patients; this meta-analysis
evaluates the magnitude of this effect.
Methods: A literature searchwas performed usingMEDLINE, Embase and the
Cochrane Collaboration Central Register of Clinical Trials from inception until
December 2014, to identify randomized controlled trials of intravenous iron
and ESA, in patients undergoing haemodialysis for end-stage kidney disease.
Dosing of IV iron in concordance with the Kidney Disease Improving Global
Outcomes guidelines was considered optimal iron therapy.
Results: Of the 28 randomized controlled trials identiﬁed, seven met the
criteria for inclusion in the meta-analysis. Results of random-effects meta-
analysis show a statistically signiﬁcant weighted mean (95% CI) difference of
1733 [3073,392] units/week inESAdose for optimal iron versus suboptimal
iron. The weighted average change in ESA dose was a reduction of 23% (range
7% to 55%) attributable to appropriate dosing of intravenous iron. A com-
parisonof intravenous iron versusoral iron/no iron (ﬁve trials) showeda greater
reduction in ESA dose, although this did not reach statistical signiﬁcance
(weighted mean difference, 95% CI: 2,433 [5183, 318] units/week). The
weighted average change in ESA dose across the ﬁve trials was a reduction of
31% (range 8% to 55%).
Conclusion: Signiﬁcant reductions in ESA dosing may be achieved with opti-
mal intravenous iron usage in the haemodialysis population, and suboptimal
iron use may require higher ESA dosing to manage anaemia.
Iron deﬁciency anaemia is common in patients with chronic
kidney disease (CKD), and this may be exacerbated by the
use of erythropoiesis-stimulating agents (ESAs).1 Patients with
CKD requiring haemodialysis (HD) are at increased risk of iron
deﬁciency anaemia as they are subject to repeated blood loss
due to retention of blood in the dialyser and blood lines, fre-
quent blood sampling for laboratory testing, and blood loss
from surgical procedures, as well as reduced iron absorption
due to inﬂammation and hepcidin upregulation, exacerbated
by concomitant medications such as gastric acid inhibitors and
phosphate binders.2,3
There have been recent concerns around the toxicity of in-
jectable ESAs (thromboembolic events and recurrent
malignancies), which could be related to higher dosages of
ESA used and consequently increased circulating blood levels
of the ESA, rather than the target haemoglobin achieved.4
Moreover, iron deﬁciency is a common cause of hyporespon-
siveness to ESAs, whether it is absolute or functional in nature.
Beyond this, there has been a call for more conservative dosing
strategies5 due to concerns with ESA-associated cardiovascular
morbidity.6–9
As such, international treatment guidelines10–13 strongly rec-
ommend the monitoring of iron status and the treatment of
iron deﬁciencywith intravenous (IV) iron±ESA in patients un-
dergoing chronic HD. Although it is generally accepted that the
treatment of iron deﬁciency with IV iron allows a reduction in
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ESA dose, quantiﬁcation of the magnitude of the reduction is
challenging, because of heterogeneity in study designs that
could allow this assessment.
Three systematic reviews of the use of IV iron in patients
with CKD have been identiﬁed in the medical literature. In
2008, Rozen-Zvi et al. assessed trials of IV iron versus oral iron
in patients with CKD, including those undergoing dialysis.14
The same group have recently repeated this exercise in the light
ofmore recent literature.15ACochrane review comparing IV iron
with oral iron in adults and children with CKD was published in
2012, 1 and a separate meta-analysis was published in 2014 to
assess the safety and efﬁcacy of IV iron in HD patients with func-
tional iron deﬁciency.16 The percentage reduction in ESA dose
frombaseline, however,was not reported in anyof these reviews.
The aim of this meta-analysis was to evaluate themagnitude
of the effect (reduction) on ESA dosing when IV iron doses,
(consistent with the Kidney Disease Improving Global Out-
comes (KDIGO) guidelines), were administered in an adult
HD population.
METHODS
Search strategy
A meta-analysis of the available literature was performed in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement.17 Published studies
indexed inMEDLINE, Embase and the Cochrane Collaboration
Central Register of Clinical Trials, Cochrane database of Sys-
tematic Reviews and Cochrane Database of Reviews of Effect
were searched from inception to December 2014 using the
search strategy described in Appendix I. A manual search for
additional studies using references from retrieved articles was
also performed.
Inclusion criteria
A systematic literature review was performed to identify ran-
domized controlled trials (RCTs) investigating the efﬁcacy and
safety of IV iron, in conjunctionwith an ESA, in patients under-
going HD for end-stage kidney failure. The participants, inter-
ventions, comparators, outcomes and study design (PICOS)
approach was used. The complete PICOS inclusion and exclu-
sion criteria are reported in Table 1. Adult patients undergoing
HD were included regardless of gender, or race, provided that
they were treated with IV iron in conjunction with an ESA.
Study eligibility was independently determined by two con-
sultants from Commercial Eyes Pty Ltd. Differing decisions
were resolved by mutual consensus.
Study validity assessment
The methodological quality of each study was assessed using
the Cochrane Handbook for Systematic Reviews of Interven-
tions.18 The presence of bias was assessed by using the ‘risk of
bias’ table (Results).
Data extraction
After application of the PICOS criteria, a standardized data
collection form was used to record the following information:
last name of the ﬁrst author, year of publication, study design,
duration of follow up, baseline iron studies, sample size,
intervention, target iron indices, ESA dose and outcomes mea-
sured. A feasibility assessment was subsequently performed to
determine which trials could be included in a meta-analysis.
A subset of trials was excluded because of populations, out-
comes or interventions that were not amenable to quantitative
comparison.
Table 1 Participants, interventions, comparators, outcomes and study design criteria for systematic literature review
P – Patients I – Interventions C – Comparators O – Outcomes S – Study design
Inclusion
criteria
Adult patients on
stable HD for CKD,
regardless of
gender, and race
■ IV iron, including but not limited
to ferric carboxymaltose, ferric
chloride, ferric gluconate, iron
dextran, iron dextrin, iron
polymaltose, iron sucrose
■ Erythropoiesis stimulating
agents, including but not limited to
epoetin alfa, epoetin beta,
darbepoetin alfa
■ IV iron, oral iron
■ Placebo
■ No iron therapy
ESA dose Placebo-controlled and active-
controlled RCTs with at least one arm
randomized to an intervention of
interest
Exclusion
criteria
Patients on
peritoneal dialysis
or not stabilized on
HD, patients with
iron overload
Studies that do not include a
treatment arm with IV iron and an
ESA
Studies that do not
include a treatment
arm with any of the
selected
comparators of
interest
Studies lacking
relevant data on any
clinical efﬁcacy, safety
and tolerability
outcomes of interest
Studies that are not written in the
English language; animal, in vitro,
pharmacokinetic, or
pharmacodynamic studies; reviews;
letters to the editor; opinions; studies
without abstracts; conference
proceedings; pooled analyses or
meta-analyses; non-randomized
studies
CKD, chronic kidney disease; ESA, erythropoiesis stimulating agent; HD, haemodialysis; IV, intravenous; RCT, randomized controlled trial.
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Statistical analysis
Review Manager 5.2 software (RevMan) from the Cochrane
Collaboration (Oxford, UK) was used for data analysis. The
mean and standard deviation of the baseline and endpoint
values were entered into RevMan, and meta-estimates were
generated. Standard deviations were estimated from standard
errors where necessary, using the RevMan internal calculators.
This provided the meta-estimate for the mean difference (MD)
or standardized mean difference between the intervention and
control arms, as well as a 95% conﬁdence interval (CI), a forest
plot and a test for overall homogeneity. Heterogeneity between
studies was measured using the I2 statistic.19
RESULTS
The search strategy yielded 208 potentially relevant articles. Of
these, 58 were duplicate records, leaving 150 citations for as-
sessment. After application of the PICOS criteria described in
Table 1, 23 met the criteria for inclusion in the systematic liter-
ature review (Fig. 1). Studies were excluded because they were
not RCTs, did not include the population, intervention or out-
come of interest orwere proceedings abstracts, guidelines or re-
views, or not written in English. There were no unresolved
conﬂicts in the review process in terms of studies included or
excluded.
Feasibility assessment
A feasibility assessment of the 23 studieswas subsequently con-
ducted, for inclusion in a meta-analysis. As the primary aim of
themeta-analysis was to determine the effect of IV iron on ESA
dose, studies which mandated that the ESA dose remain ﬁxed
throughoutwere clearly unable to inform the primary research
question. Hence, a total of 12 studies were excluded from the
analysis because they did not allow a reduction in ESA dose,
with the exception of a reduction for safety reasons only. An
additional study was excluded because it was an observational
extension to one of the preceding 12 studies. The remaining 10
studies assessed in the feasibility review had variable protocols
for dosing both IV iron and ESA therapy. Studies which com-
pared anaemiamanagement protocols, and/or included IV iron
in both treatment arms, could only be included if there was a
meaningful difference in the dose of IV iron delivered to each
group across the study duration. Accordingly, three further
studies were excluded from the analysis. Table 2 describes the
detailed characteristics of the seven included studies.
Fig. 1 Study selection ﬂow diagram. ESA,
erythropoietin stimulating agent; IV, intravenous; RCT,
randomized controlled trial.
IV iron and ESAs in haemodialysis
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ESA dose, quantiﬁcation of the magnitude of the reduction is
challenging, because of heterogeneity in study designs that
could allow this assessment.
Three systematic reviews of the use of IV iron in patients
with CKD have been identiﬁed in the medical literature. In
2008, Rozen-Zvi et al. assessed trials of IV iron versus oral iron
in patients with CKD, including those undergoing dialysis.14
The same group have recently repeated this exercise in the light
ofmore recent literature.15ACochrane review comparing IV iron
with oral iron in adults and children with CKD was published in
2012, 1 and a separate meta-analysis was published in 2014 to
assess the safety and efﬁcacy of IV iron in HD patients with func-
tional iron deﬁciency.16 The percentage reduction in ESA dose
frombaseline, however,was not reported in anyof these reviews.
The aim of this meta-analysis was to evaluate themagnitude
of the effect (reduction) on ESA dosing when IV iron doses,
(consistent with the Kidney Disease Improving Global Out-
comes (KDIGO) guidelines), were administered in an adult
HD population.
METHODS
Search strategy
A meta-analysis of the available literature was performed in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement.17 Published studies
indexed inMEDLINE, Embase and the Cochrane Collaboration
Central Register of Clinical Trials, Cochrane database of Sys-
tematic Reviews and Cochrane Database of Reviews of Effect
were searched from inception to December 2014 using the
search strategy described in Appendix I. A manual search for
additional studies using references from retrieved articles was
also performed.
Inclusion criteria
A systematic literature review was performed to identify ran-
domized controlled trials (RCTs) investigating the efﬁcacy and
safety of IV iron, in conjunctionwith an ESA, in patients under-
going HD for end-stage kidney failure. The participants, inter-
ventions, comparators, outcomes and study design (PICOS)
approach was used. The complete PICOS inclusion and exclu-
sion criteria are reported in Table 1. Adult patients undergoing
HD were included regardless of gender, or race, provided that
they were treated with IV iron in conjunction with an ESA.
Study eligibility was independently determined by two con-
sultants from Commercial Eyes Pty Ltd. Differing decisions
were resolved by mutual consensus.
Study validity assessment
The methodological quality of each study was assessed using
the Cochrane Handbook for Systematic Reviews of Interven-
tions.18 The presence of bias was assessed by using the ‘risk of
bias’ table (Results).
Data extraction
After application of the PICOS criteria, a standardized data
collection form was used to record the following information:
last name of the ﬁrst author, year of publication, study design,
duration of follow up, baseline iron studies, sample size,
intervention, target iron indices, ESA dose and outcomes mea-
sured. A feasibility assessment was subsequently performed to
determine which trials could be included in a meta-analysis.
A subset of trials was excluded because of populations, out-
comes or interventions that were not amenable to quantitative
comparison.
Table 1 Participants, interventions, comparators, outcomes and study design criteria for systematic literature review
P – Patients I – Interventions C – Comparators O – Outcomes S – Study design
Inclusion
criteria
Adult patients on
stable HD for CKD,
regardless of
gender, and race
■ IV iron, including but not limited
to ferric carboxymaltose, ferric
chloride, ferric gluconate, iron
dextran, iron dextrin, iron
polymaltose, iron sucrose
■ Erythropoiesis stimulating
agents, including but not limited to
epoetin alfa, epoetin beta,
darbepoetin alfa
■ IV iron, oral iron
■ Placebo
■ No iron therapy
ESA dose Placebo-controlled and active-
controlled RCTs with at least one arm
randomized to an intervention of
interest
Exclusion
criteria
Patients on
peritoneal dialysis
or not stabilized on
HD, patients with
iron overload
Studies that do not include a
treatment arm with IV iron and an
ESA
Studies that do not
include a treatment
arm with any of the
selected
comparators of
interest
Studies lacking
relevant data on any
clinical efﬁcacy, safety
and tolerability
outcomes of interest
Studies that are not written in the
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letters to the editor; opinions; studies
without abstracts; conference
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Statistical analysis
Review Manager 5.2 software (RevMan) from the Cochrane
Collaboration (Oxford, UK) was used for data analysis. The
mean and standard deviation of the baseline and endpoint
values were entered into RevMan, and meta-estimates were
generated. Standard deviations were estimated from standard
errors where necessary, using the RevMan internal calculators.
This provided the meta-estimate for the mean difference (MD)
or standardized mean difference between the intervention and
control arms, as well as a 95% conﬁdence interval (CI), a forest
plot and a test for overall homogeneity. Heterogeneity between
studies was measured using the I2 statistic.19
RESULTS
The search strategy yielded 208 potentially relevant articles. Of
these, 58 were duplicate records, leaving 150 citations for as-
sessment. After application of the PICOS criteria described in
Table 1, 23 met the criteria for inclusion in the systematic liter-
ature review (Fig. 1). Studies were excluded because they were
not RCTs, did not include the population, intervention or out-
come of interest orwere proceedings abstracts, guidelines or re-
views, or not written in English. There were no unresolved
conﬂicts in the review process in terms of studies included or
excluded.
Feasibility assessment
A feasibility assessment of the 23 studieswas subsequently con-
ducted, for inclusion in a meta-analysis. As the primary aim of
themeta-analysis was to determine the effect of IV iron on ESA
dose, studies which mandated that the ESA dose remain ﬁxed
throughoutwere clearly unable to inform the primary research
question. Hence, a total of 12 studies were excluded from the
analysis because they did not allow a reduction in ESA dose,
with the exception of a reduction for safety reasons only. An
additional study was excluded because it was an observational
extension to one of the preceding 12 studies. The remaining 10
studies assessed in the feasibility review had variable protocols
for dosing both IV iron and ESA therapy. Studies which com-
pared anaemiamanagement protocols, and/or included IV iron
in both treatment arms, could only be included if there was a
meaningful difference in the dose of IV iron delivered to each
group across the study duration. Accordingly, three further
studies were excluded from the analysis. Table 2 describes the
detailed characteristics of the seven included studies.
Fig. 1 Study selection ﬂow diagram. ESA,
erythropoietin stimulating agent; IV, intravenous; RCT,
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Assessment of quality of included studies
A summary of the measures taken to minimize bias across
the included studies is presented in Table 3. Although all
studies reported that randomization had taken place, few
provided details on the method used. Almost all studies were
open-label; however, as the primary outcomes in most cases
were laboratory variables (iron indices and other clinical pa-
rameters), the risk of bias from this feature is low. Almost
half the studies did not use intention-to-treat analysis
methods, with these studies reporting data only for patients
who completed the treatment protocol; a high potential for
bias could result.
Effect of IV iron on erythropoiesis-stimulating agent
dose
The intervention arms from the RCTs were categorized as opti-
mal (100–200mg IV ironperweek) and suboptimal (lower dose
IV iron (<100mg/week)), with respect to IV iron supplementa-
tion. Where both arms of the trial received IV iron (e.g. accor-
ding to different protocols), the treatment arm receiving the
highest dose of iron was considered to be the ‘optimal’ arm.
The results of the oral iron and no iron arms of Macdougall
1996 were pooled for the comparison of optimal iron and sub-
optimal iron.26 All included studies used epoetin alfa as the
ESA;however, the searcheswerenot limitedby the typeofESA.
Table 2 List of studies included in meta-analysis
Study Intervention Dose per week of IV iron Control Dose per week of IV iron
DeVita et al.20 n = 19; IV iron dextran up to 1 g
to maintain SF 400 ng/mL; ESA to
maintain Hct 32.5–36%
Mean (SD) total iron
dose1650.0 (981.2) mg
Given as 100 mg per
dialysis session
n = 17; IV iron dextran up to 1 g
to maintain SF 200 ng/mL; ESA
to maintain Hct 32.5–36%
Mean (SD) total iron
dose906.7 (953.1) mg
Given as 100 mg/r dialysis
session
Fishbane et al.21 n = 64; IV iron dextran to maintain
SF ≥ 100 μg/L and TSAT ≥20%; ESA
to maintain Hct 33–36%
Mean (SD) dose per wk47.7
(35.5) mg
Given as 100 mg per
dialysis session
n = 74; IV iron to maintain
CHr ≥ 30 pg; ESA to maintain
Hct 33–36%
Mean (SD) dose per wk22.9
(20.5) mg
Given as 100 mg per
dialysis session
Fishbane et al.22 n = 20; IV iron dextran 100 mg
twice per wk; ESA to maintain
Hct 30–34%
Not reported
Given as 200 mg/wk
n = 32; oral iron; ESA to maintain
Hct 30–34 %
Oral iron
Kaneko et al.23 n = 100; IV iron colloid 40 mg
3 x/wk if TSAT <20 %; ESA to
maintain Hct 29.5–32.5 %
Mean (SD) total iron at wk
16377.5 (361.6) mg
Given as 120 mg/wk
n = 97 IV iron colloid 40 mg three
times per wk if Chr < 32.5 pg;
ESA to maintain Hct 29.5–32.5%
Mean (SD) total iron at wk
16267.7 (353.2) mg
Given as 120 mg/wk
Kotaki et al.24 n = 15; IV iron (not speciﬁed)
100 mg/wk; ESA to maintain Hct
within three points of baseline
Not reported
Given as 100 mg/wk
n = 16; oral iron; ESA to maintain
Hct within three points of baseline
Oral iron
Li and Wang25 n = 70; IV iron sucrose 100 mg
twice/wk; ESA reduced by 25%
if Hb ≥ 11.0 g/dL
Not reported
Given as 100–200 mg/wk
n = 66; oral iron; ESA reduced by
25% if Hb ≥ 11.0 g/dL
Oral iron
Macdougall et al.26 n = 12; IV iron dextran 250 mg
every 2 weeks; ESA reduced by
33% if Hb > 12.0 g/dL, otherwise
ESA dose increased by 100% if Hb
increased <1 g/dL at 8 weeks
Not reported
Given as 250 mg every
2 weeks
n = 13; oral iron; ESA reduced by 33%
if Hb > 12.0 g/dL, otherwise ESA
dose increased by 100% if Hb increased
<1 g/dL at 8 weeksn = 12; no iron;
ESA reduced by 33% if Hb >12.0 g/dL,
otherwise ESA dose increased by 100%
if Hb increased <1 g/dL at 8 weeks
Oral iron or no iron
CHr, reticulocyte haemoglobin content; ESA, erythropoietin stimulating agent; Hb, haemoglobin, Hct, haematocrit; HD, haemodialysis; IV, intravenous; SF, serum fer-
ritin; TSAT, transferrin saturation; wk, week.
Table 3 Summary of measures undertaken to minimize bias
Study ID Sample size Randomization Blinding patients Blinding investigator Blinding assessors Basis for analysis
DeVita et al.20 n = 36 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes ITT
Fishbane et al.21 n = 157 Yes, NS Yes Yes NS, lab outcomes Other, 12% excluded
Fishbane et al.22 n = 52 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes Other, 20–36% excluded
Kaneko et al.23 n = 197 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes ITT
Kotaki et al.24 n = 37 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes Other, 16% excluded
Li and Wang25 n = 136 Yes, A NS, lab outcomes NS, lab outcomes NS, lab outcomes ITT
Macdougall et al.26 n = 38 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes Other, 3% excluded
ITT, intention to treat; NS, not speciﬁed; PP, per protocol.
SD Roger et al.
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Results of random-effects meta-analysis showed a statisti-
cally signiﬁcant weighted mean (95% CI) difference of 1733
(3073, 392) units (U)/week in ESA dose at endpoint in fa-
vour of optimal iron (Fig. 2). A simple weighted average of
the difference for the change from baseline indicates that this
difference represents a 23%dose reduction for optimal iron ver-
sus suboptimal iron prescription.
Limiting the analysis to the four RCTs of IV iron versus oral
iron provides a weighted mean (95% CI) difference of 2344
(5292, 604) U/week in ESA dose, which did not reach statis-
tical signiﬁcance, although the point estimate favours IV iron
(Fig. 3). A simple weighted average of the difference for the
change from baseline indicates that this difference represents
a 31% dose reduction for optimal iron versus suboptimal iron.
Combining the oral iron and no iron arms of Macdougall
199626 into the previous analysis had minimal impact: a
weighted mean (95% CI) difference of 2433 [5183, 318]
U/week in ESA dose (Fig. 4). This trial did not present baseline
data, and therefore, a percentage reduction from baseline could
not be calculated for this comparison, although it may be con-
cluded that it falls within the range of 23% to 31% based on
previous estimates.
The weighted average change in ESA dose across the six in-
cluded studies with baseline data was a reduction of 23%
(range 7% to 55%) attributable to appropriate dosing of
IV iron (Table 4).
Effect of IV iron on ferritin
Whilst transferrin saturation (TSAT)was not analyzed as part of
this meta-analysis, improvements in serum ferritin levels were
observed for the optimal dose group with a mean difference of
231.3 ng/mL (31.5, 494.1) and 420.9 ng/mL (175.6, 666.2)
when compared with suboptimal iron dosing or oral iron/no
iron, respectively.
DISCUSSION
This meta-analysis suggests that the use of optimal IV iron can
reduce ESA requirements by 23% when compared with sub-
optimal IV iron usage in adult HD patients. The magnitude of
reduction is more profound when IV iron is compared to oral
iron or no concomitant iron use, with a 31% reduction ob-
served. These ﬁndings equate to a potential reduction in ESA
dose of between 1733 and 2343 U/week of epoetin alfa or
equivalent. Themeta-estimates of the comparison between op-
timal and suboptimal dosing were statistically signiﬁcant in fa-
vour of optimal dosing. The comparison between IV iron and
oral/no iron did not reach statistical signiﬁcance, likely due to
the reduced power of the smaller pooled sample size, although
the direction of effect continued to favour IV iron.
Optimal iron dosing is also associated with improvements in
iron indices. The 2012 KDIGO guidelines state that if an
increase in haemoglobin and/or a reduction in ESA therapy is
desired, then the evidence supports giving IV iron when the
TSAT ≤30%and ferritin ≤500ng/mL.10 Although studies in this
meta-analysis were completed prior to the introduction of
these guidelines, in general, the ‘optimal’ dosing arms are
consistent with the KDIGO guidelines as they now exist. TSAT
was not examined, but serum ferritin increased.
In patients undergoing HD, it is estimated that iron losses
are ~1000–2000 mg/year and possibly as great as
Fig. 2 Forest plot of meta-analysis of ESA dose at endpoint, optimal versus suboptimal iron. Based on all seven included studies.20–26 Optimal iron: intravenous iron
used within a protocol consistent with KDIGO, treat to target with 100 to 200 mg/week; suboptimal iron: oral iron, no iron or lower dose intravenous iron (<100 mg IV
iron per week).
Fig. 3 Forest plot of meta-analysis of ESA dose at endpoint, IV versus oral iron.
Based on four studies of IV iron versus oral iron.22,24–26 Optimal iron: intravenous
iron used within a protocol consistent with KDIGO, treat to target with 100 to
200 mg/week; suboptimal iron: oral iron, no iron or lower dose intravenous
iron (<100 mg IV iron per week).
Fig. 4 Forest plot of meta-analysis of ESA dose at endpoint, IV versus oral Iron/
no iron. Based on four studies of IV iron versus oral/no iron.22,24–26 Optimal iron:
intravenous iron used within a protocol consistent with KDIGO, treat to target
with 100 to 200 mg/week; suboptimal iron: oral iron, no iron or lower dose
intravenous iron (<100 mg IV iron per week).
IV iron and ESAs in haemodialysis
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Assessment of quality of included studies
A summary of the measures taken to minimize bias across
the included studies is presented in Table 3. Although all
studies reported that randomization had taken place, few
provided details on the method used. Almost all studies were
open-label; however, as the primary outcomes in most cases
were laboratory variables (iron indices and other clinical pa-
rameters), the risk of bias from this feature is low. Almost
half the studies did not use intention-to-treat analysis
methods, with these studies reporting data only for patients
who completed the treatment protocol; a high potential for
bias could result.
Effect of IV iron on erythropoiesis-stimulating agent
dose
The intervention arms from the RCTs were categorized as opti-
mal (100–200mg IV ironperweek) and suboptimal (lower dose
IV iron (<100mg/week)), with respect to IV iron supplementa-
tion. Where both arms of the trial received IV iron (e.g. accor-
ding to different protocols), the treatment arm receiving the
highest dose of iron was considered to be the ‘optimal’ arm.
The results of the oral iron and no iron arms of Macdougall
1996 were pooled for the comparison of optimal iron and sub-
optimal iron.26 All included studies used epoetin alfa as the
ESA;however, the searcheswerenot limitedby the typeofESA.
Table 2 List of studies included in meta-analysis
Study Intervention Dose per week of IV iron Control Dose per week of IV iron
DeVita et al.20 n = 19; IV iron dextran up to 1 g
to maintain SF 400 ng/mL; ESA to
maintain Hct 32.5–36%
Mean (SD) total iron
dose1650.0 (981.2) mg
Given as 100 mg per
dialysis session
n = 17; IV iron dextran up to 1 g
to maintain SF 200 ng/mL; ESA
to maintain Hct 32.5–36%
Mean (SD) total iron
dose906.7 (953.1) mg
Given as 100 mg/r dialysis
session
Fishbane et al.21 n = 64; IV iron dextran to maintain
SF ≥ 100 μg/L and TSAT ≥20%; ESA
to maintain Hct 33–36%
Mean (SD) dose per wk47.7
(35.5) mg
Given as 100 mg per
dialysis session
n = 74; IV iron to maintain
CHr ≥ 30 pg; ESA to maintain
Hct 33–36%
Mean (SD) dose per wk22.9
(20.5) mg
Given as 100 mg per
dialysis session
Fishbane et al.22 n = 20; IV iron dextran 100 mg
twice per wk; ESA to maintain
Hct 30–34%
Not reported
Given as 200 mg/wk
n = 32; oral iron; ESA to maintain
Hct 30–34 %
Oral iron
Kaneko et al.23 n = 100; IV iron colloid 40 mg
3 x/wk if TSAT <20 %; ESA to
maintain Hct 29.5–32.5 %
Mean (SD) total iron at wk
16377.5 (361.6) mg
Given as 120 mg/wk
n = 97 IV iron colloid 40 mg three
times per wk if Chr < 32.5 pg;
ESA to maintain Hct 29.5–32.5%
Mean (SD) total iron at wk
16267.7 (353.2) mg
Given as 120 mg/wk
Kotaki et al.24 n = 15; IV iron (not speciﬁed)
100 mg/wk; ESA to maintain Hct
within three points of baseline
Not reported
Given as 100 mg/wk
n = 16; oral iron; ESA to maintain
Hct within three points of baseline
Oral iron
Li and Wang25 n = 70; IV iron sucrose 100 mg
twice/wk; ESA reduced by 25%
if Hb ≥ 11.0 g/dL
Not reported
Given as 100–200 mg/wk
n = 66; oral iron; ESA reduced by
25% if Hb ≥ 11.0 g/dL
Oral iron
Macdougall et al.26 n = 12; IV iron dextran 250 mg
every 2 weeks; ESA reduced by
33% if Hb > 12.0 g/dL, otherwise
ESA dose increased by 100% if Hb
increased <1 g/dL at 8 weeks
Not reported
Given as 250 mg every
2 weeks
n = 13; oral iron; ESA reduced by 33%
if Hb > 12.0 g/dL, otherwise ESA
dose increased by 100% if Hb increased
<1 g/dL at 8 weeksn = 12; no iron;
ESA reduced by 33% if Hb >12.0 g/dL,
otherwise ESA dose increased by 100%
if Hb increased <1 g/dL at 8 weeks
Oral iron or no iron
CHr, reticulocyte haemoglobin content; ESA, erythropoietin stimulating agent; Hb, haemoglobin, Hct, haematocrit; HD, haemodialysis; IV, intravenous; SF, serum fer-
ritin; TSAT, transferrin saturation; wk, week.
Table 3 Summary of measures undertaken to minimize bias
Study ID Sample size Randomization Blinding patients Blinding investigator Blinding assessors Basis for analysis
DeVita et al.20 n = 36 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes ITT
Fishbane et al.21 n = 157 Yes, NS Yes Yes NS, lab outcomes Other, 12% excluded
Fishbane et al.22 n = 52 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes Other, 20–36% excluded
Kaneko et al.23 n = 197 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes ITT
Kotaki et al.24 n = 37 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes Other, 16% excluded
Li and Wang25 n = 136 Yes, A NS, lab outcomes NS, lab outcomes NS, lab outcomes ITT
Macdougall et al.26 n = 38 Yes, NS NS, lab outcomes NS, lab outcomes NS, lab outcomes Other, 3% excluded
ITT, intention to treat; NS, not speciﬁed; PP, per protocol.
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Results of random-effects meta-analysis showed a statisti-
cally signiﬁcant weighted mean (95% CI) difference of 1733
(3073, 392) units (U)/week in ESA dose at endpoint in fa-
vour of optimal iron (Fig. 2). A simple weighted average of
the difference for the change from baseline indicates that this
difference represents a 23%dose reduction for optimal iron ver-
sus suboptimal iron prescription.
Limiting the analysis to the four RCTs of IV iron versus oral
iron provides a weighted mean (95% CI) difference of 2344
(5292, 604) U/week in ESA dose, which did not reach statis-
tical signiﬁcance, although the point estimate favours IV iron
(Fig. 3). A simple weighted average of the difference for the
change from baseline indicates that this difference represents
a 31% dose reduction for optimal iron versus suboptimal iron.
Combining the oral iron and no iron arms of Macdougall
199626 into the previous analysis had minimal impact: a
weighted mean (95% CI) difference of 2433 [5183, 318]
U/week in ESA dose (Fig. 4). This trial did not present baseline
data, and therefore, a percentage reduction from baseline could
not be calculated for this comparison, although it may be con-
cluded that it falls within the range of 23% to 31% based on
previous estimates.
The weighted average change in ESA dose across the six in-
cluded studies with baseline data was a reduction of 23%
(range 7% to 55%) attributable to appropriate dosing of
IV iron (Table 4).
Effect of IV iron on ferritin
Whilst transferrin saturation (TSAT)was not analyzed as part of
this meta-analysis, improvements in serum ferritin levels were
observed for the optimal dose group with a mean difference of
231.3 ng/mL (31.5, 494.1) and 420.9 ng/mL (175.6, 666.2)
when compared with suboptimal iron dosing or oral iron/no
iron, respectively.
DISCUSSION
This meta-analysis suggests that the use of optimal IV iron can
reduce ESA requirements by 23% when compared with sub-
optimal IV iron usage in adult HD patients. The magnitude of
reduction is more profound when IV iron is compared to oral
iron or no concomitant iron use, with a 31% reduction ob-
served. These ﬁndings equate to a potential reduction in ESA
dose of between 1733 and 2343 U/week of epoetin alfa or
equivalent. Themeta-estimates of the comparison between op-
timal and suboptimal dosing were statistically signiﬁcant in fa-
vour of optimal dosing. The comparison between IV iron and
oral/no iron did not reach statistical signiﬁcance, likely due to
the reduced power of the smaller pooled sample size, although
the direction of effect continued to favour IV iron.
Optimal iron dosing is also associated with improvements in
iron indices. The 2012 KDIGO guidelines state that if an
increase in haemoglobin and/or a reduction in ESA therapy is
desired, then the evidence supports giving IV iron when the
TSAT ≤30%and ferritin ≤500ng/mL.10 Although studies in this
meta-analysis were completed prior to the introduction of
these guidelines, in general, the ‘optimal’ dosing arms are
consistent with the KDIGO guidelines as they now exist. TSAT
was not examined, but serum ferritin increased.
In patients undergoing HD, it is estimated that iron losses
are ~1000–2000 mg/year and possibly as great as
Fig. 2 Forest plot of meta-analysis of ESA dose at endpoint, optimal versus suboptimal iron. Based on all seven included studies.20–26 Optimal iron: intravenous iron
used within a protocol consistent with KDIGO, treat to target with 100 to 200 mg/week; suboptimal iron: oral iron, no iron or lower dose intravenous iron (<100 mg IV
iron per week).
Fig. 3 Forest plot of meta-analysis of ESA dose at endpoint, IV versus oral iron.
Based on four studies of IV iron versus oral iron.22,24–26 Optimal iron: intravenous
iron used within a protocol consistent with KDIGO, treat to target with 100 to
200 mg/week; suboptimal iron: oral iron, no iron or lower dose intravenous
iron (<100 mg IV iron per week).
Fig. 4 Forest plot of meta-analysis of ESA dose at endpoint, IV versus oral Iron/
no iron. Based on four studies of IV iron versus oral/no iron.22,24–26 Optimal iron:
intravenous iron used within a protocol consistent with KDIGO, treat to target
with 100 to 200 mg/week; suboptimal iron: oral iron, no iron or lower dose
intravenous iron (<100 mg IV iron per week).
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8000 mg/year.27,28 Because of dietary restrictions and in-
creased hepcidin levels the amount of iron that HD patients
receive (from dietary sources) is likely to be less than
50 mg/month, resulting in an iron deﬁciency. Patients from
studies included in this meta-analysis were iron-deﬁcient at
commencement and therefore required higher doses, that is,
100–200 mg iron a week, to address the ongoing losses as well
as to replete stores. These doses have been termed ‘optimal’ in
our report. After repletion of the initial iron deﬁcit, lower
doses and/or less frequent administration of iron may be ap-
propriate to maintain optimal iron parameters (i.e. serum fer-
ritin and TSAT). Therefore, while currently available data limit
knowledge of optimal concomitant IV iron and ESA dose, this
analysis suggests that initial doses of ~100–200 mg IV iron per
week (when used in combination with minimized ESA dos-
ing) permits correction of anaemia. Post-repletion of iron
stores, the optimal monthly IV iron dosing, could be envisaged
to decrease to levels of approximately 100–200 mg/month,
consistent with the yearly losses, to maintain serum ferritin
and TSAT levels within targets as set by KDIGO guidelines.
Several strategies exist for IV iron delivery, including
multiple low doses potentially with dosing during each dialysis
(e.g. 10–50 mg iron with each session), single weekly doses (of
100–200mg iron) or even larger doses on amonthly or possibly
quarterly basis (i.e. 500–1000 mg iron). The doses vary signiﬁ-
cantly between institutes, although the frequency is usually
aligned with dialysis sessions.
In relation to ESA usage, KDIGO recommends that ESA
therapy should not be used to maintain a haemoglobin
above 11.5 g/dL, and not to intentionally increase the
haemoglobin above 13.0 g/dL.10 Across the included studies,
optimal iron was associated with a signiﬁcant improvement
in haemoglobin/haematocrit when compared with sub-
optimal iron.
Previous systematic reviews1,14–16 have reported on both ef-
ﬁcacy and safety of IV iron in both dialysis and non-dialysis
CKD patients. These studies had similar ﬁndings and observed
decreased ESA requirements when concomitant IV iron was
administered.
The Cochrane review1 demonstrated that haemoglobin was
signiﬁcantly increased by IV iron compared with oral iron (22
studies, 1862 patients; MD 0.90 g/dL, 95% CI 0.44 to 1.37) in
all patients and in the subgroup of dialysis patients (13 studies,
828 patients; MD 1.16 g/dL, 95% CI 0.30 to 2.02). The review
identiﬁed a signiﬁcant reduction in ESA requirements in pa-
tients treated with IV iron with a standardized MD of 0.76
[1.22 to 0.30], not further quantiﬁed, and found no signiﬁ-
cant difference inmortality. There were fewer patients who re-
ported adverse effects with IV iron, but the result did not
achieve signiﬁcance: (12 studies, 1488 patients; risk difference
0.09, 95% CI 0.19 to 0.00; I2 = 85%).
Avni et al. in a meta-analysis not restricted to CKD patients
did not ﬁnd that intravenous ironwas associatedwith increased
rates of serious adverse events or infections.29 Susantitaphong
et al. presented an exploratory analysis restricted to two RCTs
of IV iron (359 analyzable patients) indicating IV iron therapy
was not associated with an increased incidence of any adverse
event (RR = 0.88; 95%CI: 0.72–1.08; P = 0.23).16 Additionally,
IV iron resulted in signiﬁcant increases in haemoglobin of
0.54 g/dL (95% CI: 0.32–0.75 g/dL; P < 0.001), haematocrit
of 1.45% (95% CI: 0.05–2.84%; P = 0.04), serum ferritin level
of 126 ng/mL (95% CI: 63–190 ng/mL; P < 0.001), TSAT of
9.6% (95% CI: 6.9–12.2%; P < 0.001). Results of random-
effects meta-analysis of single arm studies, and arms from RCTs
(22 studies, 2147 patients) indicated a mean change in EPO
dose of 1,428 (95% CI: 2511, 345; P = 0.01) U/week.
Limiting the analysis to RCTs (two studies, 224 patients) pro-
vided a non-signiﬁcant result: mean change in EPO dose of
4,850 (95% CI: 13,113, 3,142; P = 0.25) U/week.
The review by Rozen- Zvi et al.14 concluded that compared
with oral iron, there was a signiﬁcantly greater haemoglobin
concentration in dialysis patients treated with IV iron
(weighted mean difference, 0.83 g/dL; 95% CI: 0.09 to 1.57).
Meta-regression showed a positive association between
haemoglobin level increase and IV iron dose administered
and a negative association with baseline haemoglobin concen-
tration. Data for all-cause mortality (pooled data for dialysis
and CKD patients) were sparse, but no difference was noted
(RR = 0.28; 95% CI: 0.02–5.22), and there was no difference
in adverse events between the IV-treated and oral-treated pa-
tients (RR = 0.80; 95% CI: 0.46–1.41). The observed reduction
in ESA dose was reported as a weighted mean difference of
28.21 U/kg/week (95% CI: 42.12, 14.3). Lastly, the most
recent meta-analysis by Shepshelovich et al. reported that HD
Table 4 Weighted average percentage reduction in ESA dose per week
Study Optimal iron Suboptimal iron
% Change N % Change N Weighting Difference (%)
DeVita et al.20 49 19 13 17 0.06 36
Fishbane et al.21 11 64 4 74 0.23 7
Fishbane et al.22 43 20 12 32 0.09 55
Kaneko et al.23 36 97 12 100 0.33 23
Kotaki et al.24 10 15 18 16 0.05 8
Li and Wang25 27 70 0 66 0.23 27
Weighted average change in ESA dose attributable to IV iron:(Optimal iron vs suboptimal iron) 23%
Weighted average change in ESA dose attributable to IV iron:(Intravenous iron vs oral iron/no iron) 31%
ESA, erythropoiesis stimulating agent; IV, intravenous.
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patients treated with IV verses oral iron were more likely to
reach a haemoglobin response >1 g/dL (risk ratio 2.14 [95%
CI, 1.68–2.72]. The safety analysis showed similar rates of
mortality and both serious and any adverse effects.15
The meta-estimate presented in this report provides a mean
difference in ESA dose which is also directly applicable to the
costs incurred in managing uraemic anaemia, whether in de-
veloped or under-developed healthcare systems. Intravenous
iron may also aid with overcoming ESA resistance that has
been observed when an ESA has been used without concomi-
tant IV iron. Furthermore, the reduction in ESA dose may re-
duce the risk of known ESA-related adverse effects
(thromboembolic risk, strokes and recurrent neoplasia) that
have been observed, especially with more aggressive ESA
dosing to attempt to achieve higher target haemoglobin
concentrations.8
A number of limitations of the current study should be
noted. There was high heterogeneity between the pooled
studies, in terms of effect size, as shown by the high I2, as well
as heterogeneous treatment protocols between the included
RCTs. The studies generally had a high risk of bias (as seen in
the quality assessment). The sample sizes of the included RCTs
were relatively small, and the searchwas limited to English lan-
guage studies only. Additionally, the inclusion of older studies,
not aligned with KDIGO guidelines and/or having protocol-
driven ESA dosing, may further decrease the external validity
of the pooled result.
In conclusion, this meta-analysis demonstrates that signiﬁ-
cant reductions in ESA dosing may be achieved with optimal
IV iron usage in the HD population being concurrently treated
with ESAs. In addition, suboptimal iron use may require unde-
sirably higher ESA dosing tomanage anaemia. The optimal bal-
ance between ESA dosing and IV iron dosing remains unclear
pending data on the long-term safety of IV iron, administered
at higher dosages. Thismay be clariﬁed by the largest RCT of in-
travenous iron in HD patients (PIVOTAL).30 It is an event-
driven trial comparing the incidence of hard clinical endpoints
of death, heart attack, stroke and heart failure in over 2000 pa-
tients randomized to either a proactive regimen of 400 mg IV
iron sucrose per month (with a safety cut-off) or a minimalistic
approach to IV iron (aiming to keep the serum ferritin just
above 200ng/mL and TSAT>20%). One of the secondary end-
points in this trial is the relative ESA dose requirements in the
two arms over the 2–4 years period of follow up. At the present
time, however, we do know that the use of higher amounts of
IV iron supplementation in dialysis patients allows lower doses
of ESA therapy to be used, which could potentially have posi-
tive effects on thromboembolic risk, assuming that there are
no negative effects from IV iron using this approach.
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8000 mg/year.27,28 Because of dietary restrictions and in-
creased hepcidin levels the amount of iron that HD patients
receive (from dietary sources) is likely to be less than
50 mg/month, resulting in an iron deﬁciency. Patients from
studies included in this meta-analysis were iron-deﬁcient at
commencement and therefore required higher doses, that is,
100–200 mg iron a week, to address the ongoing losses as well
as to replete stores. These doses have been termed ‘optimal’ in
our report. After repletion of the initial iron deﬁcit, lower
doses and/or less frequent administration of iron may be ap-
propriate to maintain optimal iron parameters (i.e. serum fer-
ritin and TSAT). Therefore, while currently available data limit
knowledge of optimal concomitant IV iron and ESA dose, this
analysis suggests that initial doses of ~100–200 mg IV iron per
week (when used in combination with minimized ESA dos-
ing) permits correction of anaemia. Post-repletion of iron
stores, the optimal monthly IV iron dosing, could be envisaged
to decrease to levels of approximately 100–200 mg/month,
consistent with the yearly losses, to maintain serum ferritin
and TSAT levels within targets as set by KDIGO guidelines.
Several strategies exist for IV iron delivery, including
multiple low doses potentially with dosing during each dialysis
(e.g. 10–50 mg iron with each session), single weekly doses (of
100–200mg iron) or even larger doses on amonthly or possibly
quarterly basis (i.e. 500–1000 mg iron). The doses vary signiﬁ-
cantly between institutes, although the frequency is usually
aligned with dialysis sessions.
In relation to ESA usage, KDIGO recommends that ESA
therapy should not be used to maintain a haemoglobin
above 11.5 g/dL, and not to intentionally increase the
haemoglobin above 13.0 g/dL.10 Across the included studies,
optimal iron was associated with a signiﬁcant improvement
in haemoglobin/haematocrit when compared with sub-
optimal iron.
Previous systematic reviews1,14–16 have reported on both ef-
ﬁcacy and safety of IV iron in both dialysis and non-dialysis
CKD patients. These studies had similar ﬁndings and observed
decreased ESA requirements when concomitant IV iron was
administered.
The Cochrane review1 demonstrated that haemoglobin was
signiﬁcantly increased by IV iron compared with oral iron (22
studies, 1862 patients; MD 0.90 g/dL, 95% CI 0.44 to 1.37) in
all patients and in the subgroup of dialysis patients (13 studies,
828 patients; MD 1.16 g/dL, 95% CI 0.30 to 2.02). The review
identiﬁed a signiﬁcant reduction in ESA requirements in pa-
tients treated with IV iron with a standardized MD of 0.76
[1.22 to 0.30], not further quantiﬁed, and found no signiﬁ-
cant difference inmortality. There were fewer patients who re-
ported adverse effects with IV iron, but the result did not
achieve signiﬁcance: (12 studies, 1488 patients; risk difference
0.09, 95% CI 0.19 to 0.00; I2 = 85%).
Avni et al. in a meta-analysis not restricted to CKD patients
did not ﬁnd that intravenous ironwas associatedwith increased
rates of serious adverse events or infections.29 Susantitaphong
et al. presented an exploratory analysis restricted to two RCTs
of IV iron (359 analyzable patients) indicating IV iron therapy
was not associated with an increased incidence of any adverse
event (RR = 0.88; 95%CI: 0.72–1.08; P = 0.23).16 Additionally,
IV iron resulted in signiﬁcant increases in haemoglobin of
0.54 g/dL (95% CI: 0.32–0.75 g/dL; P < 0.001), haematocrit
of 1.45% (95% CI: 0.05–2.84%; P = 0.04), serum ferritin level
of 126 ng/mL (95% CI: 63–190 ng/mL; P < 0.001), TSAT of
9.6% (95% CI: 6.9–12.2%; P < 0.001). Results of random-
effects meta-analysis of single arm studies, and arms from RCTs
(22 studies, 2147 patients) indicated a mean change in EPO
dose of 1,428 (95% CI: 2511, 345; P = 0.01) U/week.
Limiting the analysis to RCTs (two studies, 224 patients) pro-
vided a non-signiﬁcant result: mean change in EPO dose of
4,850 (95% CI: 13,113, 3,142; P = 0.25) U/week.
The review by Rozen- Zvi et al.14 concluded that compared
with oral iron, there was a signiﬁcantly greater haemoglobin
concentration in dialysis patients treated with IV iron
(weighted mean difference, 0.83 g/dL; 95% CI: 0.09 to 1.57).
Meta-regression showed a positive association between
haemoglobin level increase and IV iron dose administered
and a negative association with baseline haemoglobin concen-
tration. Data for all-cause mortality (pooled data for dialysis
and CKD patients) were sparse, but no difference was noted
(RR = 0.28; 95% CI: 0.02–5.22), and there was no difference
in adverse events between the IV-treated and oral-treated pa-
tients (RR = 0.80; 95% CI: 0.46–1.41). The observed reduction
in ESA dose was reported as a weighted mean difference of
28.21 U/kg/week (95% CI: 42.12, 14.3). Lastly, the most
recent meta-analysis by Shepshelovich et al. reported that HD
Table 4 Weighted average percentage reduction in ESA dose per week
Study Optimal iron Suboptimal iron
% Change N % Change N Weighting Difference (%)
DeVita et al.20 49 19 13 17 0.06 36
Fishbane et al.21 11 64 4 74 0.23 7
Fishbane et al.22 43 20 12 32 0.09 55
Kaneko et al.23 36 97 12 100 0.33 23
Kotaki et al.24 10 15 18 16 0.05 8
Li and Wang25 27 70 0 66 0.23 27
Weighted average change in ESA dose attributable to IV iron:(Optimal iron vs suboptimal iron) 23%
Weighted average change in ESA dose attributable to IV iron:(Intravenous iron vs oral iron/no iron) 31%
ESA, erythropoiesis stimulating agent; IV, intravenous.
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patients treated with IV verses oral iron were more likely to
reach a haemoglobin response >1 g/dL (risk ratio 2.14 [95%
CI, 1.68–2.72]. The safety analysis showed similar rates of
mortality and both serious and any adverse effects.15
The meta-estimate presented in this report provides a mean
difference in ESA dose which is also directly applicable to the
costs incurred in managing uraemic anaemia, whether in de-
veloped or under-developed healthcare systems. Intravenous
iron may also aid with overcoming ESA resistance that has
been observed when an ESA has been used without concomi-
tant IV iron. Furthermore, the reduction in ESA dose may re-
duce the risk of known ESA-related adverse effects
(thromboembolic risk, strokes and recurrent neoplasia) that
have been observed, especially with more aggressive ESA
dosing to attempt to achieve higher target haemoglobin
concentrations.8
A number of limitations of the current study should be
noted. There was high heterogeneity between the pooled
studies, in terms of effect size, as shown by the high I2, as well
as heterogeneous treatment protocols between the included
RCTs. The studies generally had a high risk of bias (as seen in
the quality assessment). The sample sizes of the included RCTs
were relatively small, and the searchwas limited to English lan-
guage studies only. Additionally, the inclusion of older studies,
not aligned with KDIGO guidelines and/or having protocol-
driven ESA dosing, may further decrease the external validity
of the pooled result.
In conclusion, this meta-analysis demonstrates that signiﬁ-
cant reductions in ESA dosing may be achieved with optimal
IV iron usage in the HD population being concurrently treated
with ESAs. In addition, suboptimal iron use may require unde-
sirably higher ESA dosing tomanage anaemia. The optimal bal-
ance between ESA dosing and IV iron dosing remains unclear
pending data on the long-term safety of IV iron, administered
at higher dosages. Thismay be clariﬁed by the largest RCT of in-
travenous iron in HD patients (PIVOTAL).30 It is an event-
driven trial comparing the incidence of hard clinical endpoints
of death, heart attack, stroke and heart failure in over 2000 pa-
tients randomized to either a proactive regimen of 400 mg IV
iron sucrose per month (with a safety cut-off) or a minimalistic
approach to IV iron (aiming to keep the serum ferritin just
above 200ng/mL and TSAT>20%). One of the secondary end-
points in this trial is the relative ESA dose requirements in the
two arms over the 2–4 years period of follow up. At the present
time, however, we do know that the use of higher amounts of
IV iron supplementation in dialysis patients allows lower doses
of ESA therapy to be used, which could potentially have posi-
tive effects on thromboembolic risk, assuming that there are
no negative effects from IV iron using this approach.
AUTHOR CONTRIBUTION
All authors have added to the meta-analysis in terms of the
following criteria: (i) substantial contributions to the
conception or design of the work; or the acquisition, analysis
or interpretation of data for the work; (ii) drafting the work
or revising it critically for important intellectual content; (iii)
ﬁnal approval of the version to be published; and (iv) agree-
ment to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part
of the work are appropriately investigated and resolved.
ACKNOWLEDGEMENTS
The meta-analysis including all statistical analysis was
performed by Commercial Eyes Pty Ltd. Study eligibility was
independently determined by two consultants from Commer-
cial Eyes Pty Ltd (Sinead Garrett, Kim Magner) with differing
decisions resolved by mutual consensus. The ﬁnal analysis
was independently veriﬁed by the Statistical Consulting Centre
at the University of Melbourne. Funding for the project was
provided by Vifor Pharma. Simon D Roger has received
speakers’ fees, honoraria and consultancy fees from several
manufacturers of ESAs and IV iron, including Amgen,
Hoffmann-La Roche, Janssen-Cilag, Novartis, Sandoz, Takeda
and Vifor Pharma. Martin Tio has no competing interests.
Hyeong-Cheon Park has received speakers’ fees, honoraria
and consultancy fees from JW Pharmaceutical, Boryung
Pharmaceutical, Kyowa Kirin and Chong Kun Dang. Hui Lin
Choong has no competing interests. Bakleong Goh has no
competing interests. Timothy R Cushway and Vanessa Stevens
are employed by Vifor Pharma. Iain CMacdougall has received
speakers’ fees, honoraria and consultancy fees from several
manufacturers of ESAs and IV iron, includingAffymax, AMAG,
Amgen, Ortho Biotech, Pharmacosmos, Hoffmann-La Roche,
Takeda and Vifor Pharma.
REFERENCES
1. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral
iron therapy for adults and children with chronic kidney disease.
Cochrane Database Syst. Rev. 2012; (1) Art. No.: CD007857. DOI:
10.1002/14651858.CD007857.pub2.
2. Fishbane S, Maesaka JK. Iron management in end-stage renal disease.
Am. J. Kidney Dis. 1997; 29: 319–333.
3. Zaritsky J, Young B, Wang HJ et al. Hepcidin – a potential novel
biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc.
Nephrol. 2009; 4: 1051–1056.
4. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and out-
comes in kidney disease and type 2 diabetes.N. Engl. J. Med. 2010; 363:
1146–1155.
5. FDA Drug Safety Communication. Modiﬁed dosing recommendations
to improve the safe use of erythropoiesis-stimulating agents (ESAs) in
chronic kidney disease; c2011 [updated 2011 Jun 26; cited 2016 Mar
20]. Available from: http://www.fda.gov/Drugs/DrugSafety/
ucm259639.htm
6. Drüeke TB, Locatelli F, ClyneN et al.Normalization of hemoglobin level
in patients with chronic kidney disease and anemia. N. Engl. J. Med.
2006; 355: 2071–2084.
7. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin
alfa in chronic kidney disease. N. Engl. J. Med. 2006; 355: 2085–2098.
8. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in
type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009; 361:
2019–2032.
IV iron and ESAs in haemodialysis
© 2016 The Authors Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Paciﬁc Society of Nephrology 7
I  ir    i  
 2   t   lished by John iley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephr logy 975
NEP_12940.indd   975 10/28/2017   9:27:53 PM
9. Koulouridis I, Alfayez M, Trikalinos TA et al. Dose of erythropoiesis-
stimulating agents and adverse outcomes in CKD: a meta-regression
analysis. Am. J. Kidney Dis. 2013; 61: 44–56.
10. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work
Group. KDIGO clinical practice guideline for anemia in chronic kidney
disease. Kidney Int. Suppl. 2012; 2: 279–335.
11. McMahon LP, Macginley R. KHA-CARI guideline. Biochemical and
haematological targets: haemoglobin concentrations in patients using
erythropoietin-stimulating agents. Nephrology 2012; 17: 17–19.
12. Macginley R, Walker R, Irving M. KHA-CARI Guideline. Use of iron in
chronic kidney disease patients. Nephrology 2013; 18: 747–749.
13. National Institute for Health and Care Excellence. Chronic kidney dis-
ease: managing anaemia; c2015 [published June 2015; cited 2016 Mar
20]. Available from: https://www.nice.org.uk/guidance/ng8 .
14. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron
supplementation for the treatment of anemia in CKD: systematic re-
view and meta-analysis. Am. J. Kidney Dis. 2008; 52: 897–906.
15. ShepshelovichD, Rozen-Zvi B, Avni T et al. Intravenous versus oral iron
supplementation for the treatment of anemia in CKD: an updated system-
atic review and meta-analysis. Am. J. Kidney Dis. 2016; pii. DOI: 10.1053/
j.ajkd.2016.04.018 [Epub ahead of print].S0272-6386(16)30125-1
16. Susantitaphong P, Alqahtani F, Jaber BL. Efﬁcacy and safety of intra-
venous iron therapy for functional iron deﬁciency anemia in hemodi-
alysis patients: a meta-analysis. Am. J. Nephrol. 2014; 39: 130–141.
17. Liberati ADG, Tetzlaff J. The PRISMA statement for reporting system-
atic reviews and meta-analyses of studies that evaluate healthcare in-
terventions: explanation and elaboration. BMJ 2009; 339: b2700.
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Inter-
vention Version 5.1.0. [Updated March 2011]. Cambridge: The Cochrane
Collaboration, 2011 .Available from: http://handbook.cochrane.org/
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsis-
tency in meta-analyses. BMJ 2003; 327: 557–560.
20. DeVita MV, Frumkin D, Mittal S et al. Targeting higher ferritin
concentrations with intravenous iron dextran lowers erythropoietin
requirement in hemodialysis patients. Clin. Nephrol. 2003; 60: 335–340.
21. Fishbane S, ShapiroW, Dutka P et al.A randomized trial of iron deﬁciency
testing strategies in hemodialysis patients.Kidney Int. 2001; 60: 2406–2411.
22. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human
erythropoietin doses by the use of chronic intravenous iron supple-
mentation. Am. J. Kidney Dis. 1995; 26: 41–46.
23. Kaneko Y, Miyazaki S, Hirasawa Y et al. Transferrin saturation versus
reticulocyte hemoglobin content for iron deﬁciency in Japanese he-
modialysis patients. Kidney Int. 2003; 63: 1086–1093.
24. Kotaki M, Uday K, Henriquez M et al.Maintenance therapy with in-
travenous iron in hemodialysis patients receiving erythropoietin. Clin.
Nephrol. 1997; 48: 63–64.
25. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis pa-
tients with renal anemia. Blood Purif. 2007; 26: 151–156.
26. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled
study of iron supplementation in patients treated with erythropoietin.
Kidney Int. 1996; 50: 1694–1699.
27. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in he-
modialysis patients. Ann. Intern. Med. 1977; 87: 710–713.
28. Macdougall IC, Bircher AJ, Eckardt KU et al. Iron management in
chronic kidney disease: conclusions from a ‘Kidney Disease: Improving
Global Outcomes’ (KDIGO) controversies conference. Kidney Int. 2016;
89: 23–39.
29. Avni T, Bieber A, Grossman A, Green Het al. The safety of intravenous
iron preparations: systematic review andmeta-analysis.Mayo Clin. Proc.
2015; 90: 12–23.
30. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/
[cited 2016 Jul 9]
APPENDIX I
Search terms*
1. exp Renal Dialysis/
2. hemodialysis.ti,kw,sh.
3. haemodialysis.ti,kw,sh.
4. 1 or 2 or 3
5. Ferric Compounds
6. Iron Compounds
7. Iron.ti,kw,sh.
8. 5 or 6 or 7
9. exp Infusions, intravenous/
10. exp Injections, intravenous/
11. intravenous$.ti,kw,sh.
12. iv.ti,kw,sh.
13. 9 or 10 or 11 or 12
14. exp random allocation/
15. exp randomized controlled trial/
16. exp Double-Blind Method/ or exp double-blind procedure/
17. random$.ti,ab,kw,sh.
18. random$.ti,ab,kw,sh.
19. 14 or 15 or 16 or 17 or 18
20. 4 and 8 and 13 and 19
21. limit 20 to humans
22. exp meta analysis/
23. meta analy$.ti,ab,kw,sh.
24. systematic$ adj2 review$
25. guideline$.ti,ab,kw,sh.
26. exp practice guideline/
27. practice guideline.pt.
28. 22 or 23 or 24 or 25 or 26 or 27
29. 4 and 8 and 13 and 28
30. 21 not 29
31. limit 30 to “review articles”
32. 30 not 31
33. 32 or 29 or 31
*Databases: Cochrane Central Register of Controlled Trials, Cochrane
DatabaseofSystematicReviews,CochraneDatabaseofReviewsofEffect,
EMBASE,MEDLINE.
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